高运宾


【摘 要】目的 观察替吉奥联合小牛脾注射液对进展期胃癌患者临床研究。方法 选我院150例进展期胃癌病患,随机分2组,各75例。试验组替吉奥联合奥沙利铂治疗,试验组联合小牛脾注射液,比较两组疗效。结果 干预后,试验组病患的疗效、生存率高于对照组,不良反应低于对照组,P<0.05。结论 对进展期胃癌病患应用吉奥联合小牛脾注射液干预,疗效佳,不良反应较小。
【关键词】替吉奥;小牛脾注射液;进展期胃癌
Abstract Objective To observe the clinical study of tiglio combined with calf spleen injection in patients with advanced gastric cancer. Methods One hundred and fifty patients with advanced gastric cancer in our hospital were randomly divided into two groups with 75 cases each. The experimental group was treated with tigio combined with oxaliplatin, and the experimental group was combined with calf spleen injection. Results After the intervention, the curative effect and survival rate of patients in the experimental group were higher than those in the control group, and adverse reactions were lower than those in the control group, P <0.05. Conclusion The application of Goo combined with calf spleen injection in patients with advanced gastric cancer has good effect and less adverse reactions.
Key words Tegio; calf spleen injection; advanced gastric cancer
胃癌不僅是临床常见病,而且对患者的危害极大。目前临床治疗肺癌的主要方式为化疗,化疗治疗的有效率是20%-90%[1]。进展期胃癌的预后较差,研究表明化疗联合新辅化疗可以提升患者的预后[2]。本文旨在进一步研究替吉奥联合小牛脾注射液对进展期胃癌患者治疗的疗效以及预后和不良反应,具体研究结果如下:
1 资料及方法
1.1 一般资料
经医院伦理委员会的批准实施,选2018年12月到2019年12月我院收治的150例进展期胃癌入选本次研究,病患按照1:1进行等分,共分成2组。试验组病患的年龄区间:41-72(63.41±9.24)岁;男35例,女40例;对照组病患的年龄区间:43-74(61.66±13.23)岁;男37例,女38例。比较一般资料,不存在统计学上的差异,P>0.05。排除标准[3]:(1)患者昏迷或存在精神障碍;(2)恶性肿瘤;(3)严重的肾肝功能不全;(4)药物禁忌;(5)不署知情协议书。
1.2 治疗方法
(1)对照组:患者予以替吉奥胶囊(H20113281,江苏恒瑞医药股份有限公司生产)口服治疗, 40mg/次,bid;奥沙利铂(H20000686,南京制药厂有限公司)130mg/次,qd。(2)试验组:患者予以替吉奥、奥沙利铂(具体用法同对照组)、以及小牛脾注射液(H22026121,吉林敖东洮南药业股份有限公司)静脉注射治疗,8ml/次,qd。用药持续21天。……p>